Physician profile
Muhammad A Munir
NPI 1134136526
$9,333.40
in general payments reported to CMS, 2019-2025
48 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $1,066 · 2021: $331 · 2022: $393 · 2023: $1,038 · 2024: $4,397 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,686 · Travel and Lodging: $2,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,686.08 |
| Travel and Lodging | $2,651.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,255.33 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Spectra Wavewriter |
| Spinal Simplicity, LLC | $1,434.00 | 2024-2025 | Ha Minuteman G3-R |
| Curonix LLC | $1,143.78 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medtronic, INC. | $667.02 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Abbvie INC. | $582.61 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $283.68 | 2020-2025 | Belbuca, Xtampza |
| Painteq LLC | $264.04 | 2023-2024 | Painteq |
| Amgen INC. | $191.91 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $187.76 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $182.84 | 2019-2025 | |
| Abbott Laboratories | $182.06 | 2019-2021 | |
| Nevro Corp. | $179.24 | 2019-2024 | Senza |
| Ibsa Pharma INC. | $128.73 | 2022-2023 | Tirosint, Licart |
| Pfizer INC. | $124.37 | 2020-2025 | |
| Averitas Pharma INC. | $114.80 | 2023-2025 | Qutenza |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.